Tag
A pivotal Phase 2 study demonstrates that derazantinib yields meaningful responses and progression-free survival in FGFR2-aberrant advanced intrahepatic cholangiocarcinoma, with an acceptable safety profile, supporting its role as a targete
A novel T classification system based on tumor invasion depth significantly improves prognostic stratification for biliary tract cancers around the cystic duct junction, unifying diverse cancer types under the junctional cholangiocarcinoma
This study delineates three unique molecular subtypes of cholangiocarcinoma via integrated multiomic and machine learning methodologies, highlighting TNK1 kinase as a promising targeted therapy in a metabolic subtype.
A landmark six-year study involving over 2,000 patients at 28 institutions demonstrates that next-generation sequencing of ERCP-obtained specimens achieves 82% sensitivity for neoplastic bile duct strictures, nearly doubling traditional pat
This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT
A Phase 2 trial demonstrates that tinengotinib, a multi-kinase inhibitor, shows significant clinical activity in patients with advanced cholangiocarcinoma who have progressed on prior FGFR inhibitors, particularly those with acquired resist
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
